Global Liver Institute Welcomes Larry R. Holden as CEO
The Board of Directors of Global Liver Institute (GLI), the premier liver patient advocacy organization, has appointed Larry R. Holden as the organization’s Chief Executive Officer, as of September 2024.
More Than a Cure, a Path to Improvement: Hepatitis C Treatment
Hepatitis C infection, an infection of the liver by the hepatitis C virus, is a major global health concern, affecting millions.
Understanding the New EASL-EASD-EASO Guidelines on MASLD
Clinical practice guidelines are evidence-based recommendations developed through systematic review and consensus to help healthcare providers and patients make informed decisions about the most appropriate treatment options for specific health conditions.
GLI Celebrates FDA Approval of Livdelzi®, an Option in Personalizing PBC Treatment
Global Liver Institute (GLI) celebrates the expansion of treatment options for patients with primary biliary cholangitis (PBC) after the U.S. Food and Drug Administration decided to provide accelerated approval of Gilead Science’s seladelpar (Livdelzi®) for primary biliary cholangitis (PBC).
Catch Up on Possible End-of-Year Legislative Action and FY 2025 Appropriations Updates – Liver Health Policy Update
Congress is entering the August recess period. Nevertheless, patients are increasingly signaling to policymakers their frustration related to coverage challenges and over-zealous utilization management practices such as non-medical switching and other barriers to care. And appropriations bills are out for FY 2025!